These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10543144)

  • 1. [Platinum derivatives].
    Sasaki Y
    Nihon Rinsho; 1999 Sep; 57 Suppl():425-7. PubMed ID: 10543144
    [No Abstract]   [Full Text] [Related]  

  • 2. [Platinum derivatives].
    Sasaki Y
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
    J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of platinum-based drugs with native biologically relevant proteins.
    Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
    Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic properties of platinium derivatives].
    Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
    Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
    Zucca E; Cattaneo MT; Cavalli F; Guaitani A; Filipazzi V; Bartosek I
    G Ital Chemioter; 1985; 32(1):25-8. PubMed ID: 3913618
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
    Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
    Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A shotgun approach for the identification of platinum-protein complexes.
    Moraleja I; Moreno-Gordaliza E; Esteban-Fernández D; Mena ML; Linscheid MW; Gómez-Gómez MM
    Anal Bioanal Chem; 2015 Mar; 407(9):2393-403. PubMed ID: 25618759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS.
    Nguyen TT; Ostergaard J; Stürup S; Gammelgaard B
    Int J Pharm; 2013 Jun; 449(1-2):95-102. PubMed ID: 23583709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
    Sooriyaarachchi M; Narendran A; Gailer J
    Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capillary liquid chromatography with UV detection using N,N-diethyl dithiocarbamate for determining platinum-based antitumor drugs in plasma.
    Otsuki Y; Kotani A; Kusu F
    Chem Pharm Bull (Tokyo); 2012; 60(5):665-9. PubMed ID: 22689405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
    Oprea A; Bazzazi H; Kangarloo B; Wolff JE
    Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
    Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
    Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro plasma binding of some second generation antitumor platinum complexes.
    Momburg R; Bourdeaux M; Sarrazin M; Roux F; Briand C
    Eur J Drug Metab Pharmacokinet; 1985; 10(1):77-83. PubMed ID: 4040860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification and clinical application of carboplatin in plasma ultrafiltrate.
    Downing K; Jensen BP; Grant S; Strother M; George P
    J Pharm Biomed Anal; 2017 May; 138():373-377. PubMed ID: 28260690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.